Lack of evidence for the transmission of hepatitis E virus by coagulation factor concentrates based on seroprevalence data

ConclusionHEV seroprevalence was significantly higher in the blood donors than in the patients with a history of coagulation factor concentrate administration. In one of two patients with detectable anti‐HEV IgG antibodies, the coagulation factor concentrate was not the probable source of infection. Our data suggest that HEV is efficiently inactivated during the manufacturing process of coagulation factor concentrates. Thus, testing for the presence of HEV RNA in plasma donated for the preparation of coagulation factor concentrates may not be necessary.

Source: Transfusion Medicine - October 1, 2017 Category: Hematology Authors: D. Juhl, U. Nowak ‐Göttl, J. Blümel, S. Görg, H. Hennig Tags: ORIGINAL ARTICLE Source Type: research